Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease

INTRODUCTION: Most patients (70%) with limited-stage SCLC (LS-SCLC) who are treated with curative-intent therapy suffer disease relapse and cancer-related death. We evaluated circulating tumor DNA (ctDNA) as a predictor of disease relapse and death after definitive therapy in patients with LS-SCLC....

Descripción completa

Detalles Bibliográficos
Autores principales: Iams, Wade T., Kopparapu, Prasad R., Yan, Yingjun, Muterspaugh, Anel, Zhao, Zhiguo, Chen, Heidi, Cann, Christopher, York, Sally, Horn, Leora, Ancell, Kristin, Wyman, Kenneth, Bertucci, Caterina, Shaffer, Tristan, Hodsdon, Lauren A., Garg, Kavita, Hosseini, Seyed Ali, Lim, Lee P., Lovly, Christine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474488/
https://www.ncbi.nlm.nih.gov/pubmed/34589931
http://dx.doi.org/10.1016/j.jtocrr.2020.100024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474488/
https://www.ncbi.nlm.nih.gov/pubmed/34589931
http://dx.doi.org/10.1016/j.jtocrr.2020.100024

Ejemplares similares